Please login to the form below

Not currently logged in


This page shows the latest antidote news and features for those working in and with pharma, biotech and healthcare.

Boston Scientific makes $4.2bn play for UK’s BTG

Boston Scientific makes $4.2bn play for UK’s BTG

BTG also has a small portfolio of pharmaceutical products, including snake bite antivenin CroFab and antidotes for digoxin overdose and methotrexate toxicity, which is something of a departure from Boston Scientific

Latest news

More from news
Approximately 1 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence, collaboration. 237.5. Portola Pharmaceuticals/  HealthCare Royalty Partners. AndexXa (andexanet alfa) - Factor Xa inhibitor antidote (phase IIIb/IV).

  • Deal Watch February 2016 Deal Watch February 2016

    merger. 106. † Portola Pharmaceuticals/ BMS| Pfizer. andexanet alfa as an antidote for apixaban and other Factor Xa inhibitors (pre-reg).

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Portola is also developing PRT 064445, which is an antidote designed to reverse the activity of factor Xa inhibitors and low molecular weight heparins. ... Idrabiotaparinux sodium has the same pentasaccharidic structure as idraparinux sodium but has an

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • How to be a patient

    We can therefore provide a service by offering impartial, code-compliant information as an antidote to the 'alt-med' lobby.  .

  • Ogilvy Healthworld

    'We have a habit of divine discontent with our performance.It is an antidote to smugness.'So said David Ogilvy.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....